Richard I Steinhart
CIK 1293789 · Chief Financial Officer · last filed 2026-09-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BTAI price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
555 LONG WHARF DRIVE, 12TH FLOOR
NEW HAVEN, CT 06511
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ATNM | Director | 63,116 | $1.40 | $88.4K | $5.0K | 12 | 2026-09-04 |
| BioXcel Therapeutics, Inc. (BTAI) Delisted | Chief Financial Officer | 26,335 | $0.07 | $1.9K | -$364.6K | 32 | 2026-06-17 |
| ATOS | Director | 10,000 | $2.45 | $24.5K | $0 | 13 | 2026-05-14 |
| STRATA Skin Sciences, Inc. (MELA) Delisted | Chief Financial Officer | 25,000 | — | — | $8.7K | 6 | 2013-08-08 |
| TG THERAPEUTICS, INC. (MHA) Delisted | Director | 5,633 | — | — | $0 | 1 | 2007-01-31 |
Recent Filings · Page 2 of 8
75 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-08-05 | BioXcel Therapeutics, Inc. (BTAI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-07-22 | BioXcel Therapeutics, Inc. (BTAI) Delisted | Mixed | +5,000 | $0 | EDGAR |
| 2025-06-16 | BioXcel Therapeutics, Inc. (BTAI) Delisted | Exer (M) | +68 | $0 | EDGAR |
| 2025-05-16 | ATOS | Grant (A) | — | $0 | EDGAR |
| 2025-04-02 | ATNM | Disp (D) | — | $0 | EDGAR |
| 2025-04-01 | BioXcel Therapeutics, Inc. (BTAI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-03-17 | BioXcel Therapeutics, Inc. (BTAI) Delisted | Exer (M) | +65 | $0 | EDGAR |
| 2025-01-10 | BioXcel Therapeutics, Inc. (BTAI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-12-17 | BioXcel Therapeutics, Inc. (BTAI) Delisted | Mixed | +506 | -$207 | EDGAR |
| 2024-12-16 | BioXcel Therapeutics, Inc. (BTAI) Delisted | Notice (144/A) | −430 | -$154 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.